Table 2.
Patient demographics and baseline characteristics for the CheckMate 451 HPD analysis population
| Characteristic | Placebo (n=175) | Nivolumab 240 mg (n=177) | Nivolumab 1 mg/kg+ipilimumab 3 mg/kg (n=179) |
| Age, years, median (range) | 64 (44–81) | 65 (34–84) | 64 (39–85) |
| Female, n (%) | 60 (34.3) | 62 (35.0) | 60 (33.5) |
| Race, n (%) | |||
| White | 127 (72.6) | 138 (78.0) | 141 (78.8) |
| Black or African American | 1 (0.6) | 2 (1.1) | 1 (0.6) |
| Asian | 42 (24.0) | 35 (19.8) | 34 (19.0) |
| Other | 5 (2.9) | 2 (1.1) | 3 (1.7) |
| ECOG PS, n (%) | |||
| 0 | 61 (34.9) | 77 (43.5) | 78 (43.6) |
| 1 | 114 (65.1) | 100 (56.5) | 101 (56.4) |
| Region, n (%) | |||
| US/Canada | 35 (20.0) | 38 (21.5) | 38 (21.2) |
| Asia | 41 (23.4) | 34 (19.2) | 33 (18.4) |
| Europe | 68 (38.9) | 81 (45.8) | 76 (42.5) |
| Rest of world | 31 (17.7) | 24 (13.6) | 32 (17.9) |
| Type of first-line, platinum-based therapy, n (%)* | |||
| Carboplatin | 103 (58.9) | 118 (66.7) | 107 (59.8) |
| Cisplatin | 78 (44.6) | 62 (35.0) | 82 (45.8) |
| Baseline tumor size, cm | |||
| Mean (SD) | 5.7 (4.2) | 5.2 (3.7) | 5.1 (4.3) |
| Median (range) | 4.4 (1.2–21.9) | 4.0 (1.0–18.5) | 3.6 (1.0–28.6) |
*Patients may have received more than one type of platinum compound.
ECOG PS, Eastern Cooperative Oncology Group performance status; HPD, hyperprogressive disease.